CN102818890A - 一种检测系统性红斑狼疮患者自身抗体的方法 - Google Patents

一种检测系统性红斑狼疮患者自身抗体的方法 Download PDF

Info

Publication number
CN102818890A
CN102818890A CN 201110155458 CN201110155458A CN102818890A CN 102818890 A CN102818890 A CN 102818890A CN 201110155458 CN201110155458 CN 201110155458 CN 201110155458 A CN201110155458 A CN 201110155458A CN 102818890 A CN102818890 A CN 102818890A
Authority
CN
China
Prior art keywords
antibody
lupus erythematosus
patient
systemic lupus
erythematosus patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 201110155458
Other languages
English (en)
Inventor
黄静芳
徐红星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Vocational Health College
Original Assignee
Suzhou Vocational Health College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Vocational Health College filed Critical Suzhou Vocational Health College
Priority to CN 201110155458 priority Critical patent/CN102818890A/zh
Publication of CN102818890A publication Critical patent/CN102818890A/zh
Pending legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

本发明公开了一种检测系统性红斑狼疮患者自身抗体的方法,具体步骤为,首先用间接免疫荧光法分别检测系统性红斑狼疮患者的抗核抗体及双链DNA,然后用欧蒙免疫印迹法测定抗核抗体谱,最后用酶联免疫吸附试验检测系统性红斑狼疮患者的单链DNA。本发明的检测系统性红斑狼疮患者自身抗体的方法,简化了现有的检测方法,提高了检测效率及确诊率,有助于系统性红斑狼疮的临床诊断和治疗。

Description

一种检测系统性红斑狼疮患者自身抗体的方法
技术领域
    本发明涉及医学领域,具体涉及一种检测系统性红斑狼疮患者自身抗体的方法。
 
背景技术
系统性红斑狼疮是一种急骤或缓慢发病、侵犯多系统多器官的自身免疫性疾病。其主要免疫学特征是产生多种自身抗体,形成免疫复合物而致病。自身抗体的检测是系统性红斑狼疮诊断的重要指标,目前国内许多医院已经开展了自身抗体的检测。明确系统性红斑狼疮患者抗核抗体的滴度、荧光模式及其与各种自身抗体之间的相互关系,对系统性红斑狼疮的诊断、治疗的有很高的临床价值。
基于以上问题,发明一种检测系统性红斑狼疮患者自身抗体的方法,已成为本技术领域内丞待解决的问题。
 
发明内容
 本发明的目的在于提供了一种检测系统性红斑狼疮患者自身抗体的方法,解决了现有技术中系统性红斑狼疮的诊断方法比较复杂的问题。
     本发明的一种检测系统性红斑狼疮患者自身抗体的方法,具体步骤为:
步骤1)以Hep-2/大鼠肝细胞为基质,用间接免疫荧光法检测系统性红斑狼疮患者的抗核抗体,测定四个滴度:1:100,1:320,1:1000,1:3200;
步骤2)以短膜虫为基质,用间接免疫荧光法检测系统性红斑狼疮患者的双链DNA;
步骤3)用欧蒙免疫印迹法测定抗核抗体谱;
    步骤4)用酶联免疫吸附试验检测系统性红斑狼疮患者的单链DNA。  
有益效果:经检测系统性红斑狼疮患者自身抗体的方法,化了现有的检测方法,提高了检测效率及确诊率,有助于系统性红斑狼疮的临床诊断和治疗。
 
具体实施方式
实施例1
以2008年至2010年苏州市立医院门诊或住院病人中的109例系统性红斑狼疮患者为检测对象,其中女性95例,男性14例,年龄14-82岁,平均年龄43岁。所有系统性红斑狼疮患者病例均符合美国风湿病协会的诊断标准。
具体检测步骤如下:
步骤1)以Hep-2/大鼠肝细胞为基质,用间接免疫荧光法检测系统性红斑狼疮患者的抗核抗体,测定四个滴度:1:100,1:320,1:1000,1:3200;
步骤2)以短膜虫为基质,用间接免疫荧光法检测系统性红斑狼疮患者的双链DNA;
步骤3)用欧蒙免疫印迹法测定抗核抗体谱(抗RNP抗体、抗Sm抗体、抗SSA抗体、抗SSB抗体、抗Scl-70抗体、抗CENPB抗体、抗ANuA抗体、抗His抗体、抗Rib.P抗体);
    步骤4)用酶联免疫吸附试验检测系统性红斑狼疮患者的单链DNA。  
 所有试剂均由德国欧蒙公司提供,具体操作按说明书进行。
    检测结果如下:
1.抗核抗体的滴度、荧光模式检测结果
109例系统性红斑狼疮(SLE)患者中,抗核抗体(ANA)的阳性为107例,阳性率为98.2%,大于等于1:1000的抗核抗体高滴度患者有77例,阳性率达70.6%,其中43.1%的系统性红斑狼疮患者的抗核抗体滴度为1:1000;其荧光核型有颗粒型、均质型、颗粒合并均质型、颗粒合并核仁型、颗粒合并着丝点型、颗粒合并胞浆型,以颗粒型和均质型为主,分别占56.9%和33.9%。具体结果见表1。
  
Figure DEST_PATH_IMAGE002AA
2.系统性红斑狼疮(SLE)患者中各种自身抗体检测结果
抗核抗体谱中,抗SSA抗体的阳性率最高,为57.8%;抗RNP抗体、抗Sm抗体、抗ANuA抗体、抗His抗体、抗Rib.P抗体的阳性率也较高,分别为35.8%、32.1%、40.4%、37.6%、32.1%;抗Scl-70抗体、抗CENPB抗体的阳性率较低。抗ds-DNA抗体和抗ss-DNA抗体也有比较高的阳性率,达33.9%、54.1%。具体结果见表2。
 
Figure DEST_PATH_IMAGE004AA
3.系统性红斑狼疮(SLE)患者自身抗体在各种荧光核型中的分布
    各种自身抗体中,抗RNP抗体、抗Sm抗体、抗SSA抗体、抗SSB抗体、抗ss-DNA抗体,其荧光模式主要表现为颗粒型,分别占69.2%、74.3%、61.9%、63.0%、59.3%;抗ANuA抗体、抗His抗体、抗Rib.P抗体、抗ds-DNA抗体,其荧光模式表现为颗粒型或均质型各一半;抗Scl-70抗体主要为均质型、抗CENPB抗体为着丝点型。具体结果见表3。
Figure DEST_PATH_IMAGE006AA
由此得出如下结论:
抗核抗体属非特异指标,可在许多疾病出现,但其滴度可作为系统性红斑狼疮患者活动性的指标之一。本109例系统性红斑狼疮患者中,抗核抗体(ANA)的阳性率为98.2%,大于等于1:1000的抗核抗体高滴度患者的阳性率达70.6%,其中43.1%的系统性红斑狼疮患者患者的抗核抗体滴度为1:1000。说明受检患者多数为初发病例或活动期患者,随着病情的缓解,抗核抗体滴度随之下降。所以,定期检查抗核抗体滴度有助于病情的监控。抗核抗体靶抗原检测由传统的细胞核扩展到现在的整个细胞,包括细胞核、细胞浆等。本检测结果显示了六种荧光模式,包括颗粒型、均质型、颗粒合并均质型、颗粒合并核仁型、颗粒合并着丝点型、颗粒合并胞浆型,以常见的颗粒型和均质型为主。
系统性红斑狼疮免疫学的显著特点为出现各种自身抗体。本方法共检测出十一种自身抗体,分别为抗RNP抗体、抗Sm抗体、抗SSA抗体、抗SSB抗体、抗ANuA抗体、抗His抗体、抗Rib.P抗体、抗Scl-70抗体、抗CENPB抗体、抗ds-DNA抗体和抗ss-DNA抗体。其中抗SSA抗体的阳性率最高,为57.8%;其次,抗RNP抗体、抗Sm抗体、抗ANuA抗体、抗His抗体、抗Rib.P抗体的阳性率也较高,抗Scl-70抗体、抗CENPB抗体的阳性率较低。抗ds-DNA抗体和抗ss-DNA抗体也有比较高的阳性率。各种自身抗体中,抗RNP抗体、抗Sm抗体、抗SSA抗体、抗SSB抗体、抗ss-DNA抗体,其荧光模式主要表现为颗粒型;抗ANuA抗体、抗His抗体、抗Rib.P抗体、抗ds-DNA抗体,其荧光模式表现为颗粒型或均质型各一半;抗Scl-70抗体主要为均质型、抗CENPB抗体为着丝点型。故根据荧光模式可初步判断相应抗体的性质范围,但应注意一种抗体可出现不同的荧光模式,不同的抗体也可出现相同的荧光模式。
系统性红斑狼疮的起始和发病机制尚不清楚,其诊断较为复杂。通过检测抗核抗体荧光模式、抗核抗体的滴度及各种自身抗体的检测,有助于系统性红斑狼疮的临床诊断和治疗。
上述实施例只是为了说明本发明的技术构思及特点,其目的是在于让本领域内的普通技术人员能够了解本发明的内容并据以实施,并不能以此限制本发明的保护范围。凡是根据本发明内容的实质所作出的等效的变化或修饰,都应涵盖在本发明的保护范围内。

Claims (2)

1.  一种检测系统性红斑狼疮患者自身抗体的方法,其特征在于,具体步骤为:
步骤1)以Hep-2/大鼠肝细胞为基质,用间接免疫荧光法检测系统性红斑狼疮患者的抗核抗体,测定四个滴度:1:100,1:320,1:1000,1:3200;
步骤2)以短膜虫为基质,用间接免疫荧光法检测系统性红斑狼疮患者的双链DNA;
步骤3)用欧蒙免疫印迹法测定抗核抗体谱;
    步骤4)用酶联免疫吸附试验检测系统性红斑狼疮患者的单链DNA。
2.根据权利要求1所述的检测系统性红斑狼疮患者自身抗体的方法,其特征在于,所述步骤3)中,抗核抗体谱包括抗RNP抗体、抗Sm抗体、抗SSA抗体、抗SSB抗体、抗Scl-70抗体、抗CENPB抗体、抗ANuA抗体、抗His抗体和抗Rib.P抗体。
CN 201110155458 2011-06-10 2011-06-10 一种检测系统性红斑狼疮患者自身抗体的方法 Pending CN102818890A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201110155458 CN102818890A (zh) 2011-06-10 2011-06-10 一种检测系统性红斑狼疮患者自身抗体的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201110155458 CN102818890A (zh) 2011-06-10 2011-06-10 一种检测系统性红斑狼疮患者自身抗体的方法

Publications (1)

Publication Number Publication Date
CN102818890A true CN102818890A (zh) 2012-12-12

Family

ID=47303129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201110155458 Pending CN102818890A (zh) 2011-06-10 2011-06-10 一种检测系统性红斑狼疮患者自身抗体的方法

Country Status (1)

Country Link
CN (1) CN102818890A (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103409372A (zh) * 2013-04-01 2013-11-27 北京大学人民医院 一种稳定表达mDNA的细胞
CN104597244A (zh) * 2013-10-30 2015-05-06 吴庄民 基于表位抗原肽的抗mtDNA抗体酶联免疫的检测方法及其应用
CN107110861A (zh) * 2014-08-08 2017-08-29 阿勒格尼-辛格研究所 作为诊断性生物标志物的抗淋巴细胞的自身抗体
CN108333347A (zh) * 2017-01-19 2018-07-27 深圳市新产业生物医学工程股份有限公司 抗核抗体靶抗原偶联物试剂、其制备方法、包含其的试剂盒及应用
CN110412290A (zh) * 2019-07-29 2019-11-05 冯仕品 Sle总体疾病活动度和肾脏疾病活动度信息检测系统

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103409372A (zh) * 2013-04-01 2013-11-27 北京大学人民医院 一种稳定表达mDNA的细胞
CN104597244A (zh) * 2013-10-30 2015-05-06 吴庄民 基于表位抗原肽的抗mtDNA抗体酶联免疫的检测方法及其应用
CN107110861A (zh) * 2014-08-08 2017-08-29 阿勒格尼-辛格研究所 作为诊断性生物标志物的抗淋巴细胞的自身抗体
CN108333347A (zh) * 2017-01-19 2018-07-27 深圳市新产业生物医学工程股份有限公司 抗核抗体靶抗原偶联物试剂、其制备方法、包含其的试剂盒及应用
CN110412290A (zh) * 2019-07-29 2019-11-05 冯仕品 Sle总体疾病活动度和肾脏疾病活动度信息检测系统

Similar Documents

Publication Publication Date Title
Ebbo et al. Pathologies associated with serum IgG4 elevation
Berti et al. The epidemiology of antineutrophil cytoplasmic autoantibody–associated vasculitis in Olmsted County, Minnesota: a twenty‐year US population–based study
Arkema et al. Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case–control study
Yadav et al. The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease
Cox et al. Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features
CN102818890A (zh) 一种检测系统性红斑狼疮患者自身抗体的方法
Olsen et al. Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment
Alghoul et al. The current status of molecular biomarkers for inflammatory bowel disease
Bartsch et al. The combination of MiRNA-196b, LCN2, and TIMP1 is a potential set of circulating biomarkers for screening individuals at risk for familial pancreatic cancer
Salaffi et al. The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia
Kimber-Trojnar et al. The potential of non-invasive biomarkers for early diagnosis of asymptomatic patients with endometriosis
Davies et al. Patients with primary Sjögren's syndrome have alterations in absolute quantities of specific peripheral leucocyte populations
Zhu et al. The expansion of myeloid‐derived suppressor cells is associated with joint inflammation in rheumatic patients with arthritis
Ghaffari et al. Association among thyroid dysfunction, asthma, allergic rhinitis and eczema in children with alopecia areata
Iwasaki et al. Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis
Su et al. The association among leukocyte apoptosis, autoantibodies and disease severity in systemic lupus erythematosus
Huang et al. Identification of lncRNAs associated with the pathogenesis of ankylosing spondylitis
Cheemarla et al. Nasal host response-based screening for undiagnosed respiratory viruses: a pathogen surveillance and detection study
Guimarães et al. Diagnostic test accuracy of novel biomarkers for lupus nephritis—An overview of systematic reviews
Cui et al. Diagnostic values of miR-221-3p in serum and cerebrospinal fluid for post-stroke depression and analysis of risk factors
Yamashiro et al. Exosome-derived microRNAs from mouthrinse have the potential to be novel biomarkers for Sjögren syndrome
Jenkins et al. Malaria, mental disorders, immunity and their inter-relationships-A cross sectional study in a household population in a health and demographic surveillance site in Kenya
Koc et al. Eosinophil Levels, Neutrophil‐Lymphocyte Ratio, and Platelet‐Lymphocyte Ratio in the Cytokine Storm Period of Patients with COVID‐19
Becker et al. Constitutional trisomy 8 and Behçet syndrome
Kmetzsch et al. MicroRNA signatures in genetic frontotemporal dementia and amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121212